Posted by Michael Wonder on 26 Oct 2024
Iterum Therapeutics receives US FDA approval of Orlynvah (oral sulopenem) for the treatment of uncomplicated urinary tract infections
25 October 2024 - Orlynvah is the first oral penem approved for use in the US and the second FDA approved treatment for uncomplicated urinary tract infections in the past two decades.
Iterum Therapeutics today announced that the US FDA has approved Iterum’s new drug application for Orlynvah (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options.
